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Oral atorvastatin has prevented or reversed paralysis in the multiple sclerosis (MS) model experimental autoimmune
encephalomyelitis (EAE), and reduced development of new MS lesions in clinical trials. Besides inhibiting development
of encephalitogenic T cells, atorvastatin treatment of EAE has been associated with an induction of anti-inflammatory
myelin-reactive T-helper type (Th)-2 cells. To investigate the clinical significance of atorvastatin-mediated Th2
differentiation, we first evaluated atorvastatin treatment in interleukin (IL)-4 green fluorescent protein-enhanced
transcript (4-GET) reporter mice. Atorvastatin treatment failed to induce IL-4-producing Th2 cells in vivo; however,
when T cells from atorvastatin-treated 4-GET mice were reactivated in vitro, T cells preferentially differentiated into
Th2 cells, while antigen-specific T-cell proliferation and secretion of proinflammatory cytokines (interferon gamma,
IL-17, tumor necrosis factor and IL-12) were reduced. Oral atorvastatin also prevented or reversed EAE in signal
transducer and activator of transcription 6-deficient (STAT6−/−) mice, which cannot generate IL-4-producing Th2
cells. Further, atorvastatin treatment did not induce or expand Foxp3+ regulatory T cells in either wild-type or
STAT6−/− mice. In vivo proliferation of T cells, as measured by incorporation of bromodeoxyuridine, was inhibited
in atorvastatin-treated wild-type and STAT6−/− mice. These data imply that atorvastatin ameliorates central nervous
system autoimmune disease primarily by inhibiting proliferation of proinflammatory encephalitogenic T cells, and
not simply through induction of anti-inflammatory Th2 cells. This cytostatic effect may be a relevant mechanism of
action when considering use of statins in MS and other inflammatory conditions.Introduction
Statins are inhibitors of the enzyme 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG-CoA) reductase that are
widely prescribed to lower serum cholesterol [1]. Besides
their metabolic properties, statins attracted interest for
their immunomodulatory potential [2]. Statins are clinic-
ally beneficial in various models of autoimmune diseases,
such as experimental arthritis [3], experimental auto-
immune uveoretinitis [4], experimental autoimmune* Correspondence: zamvil@ucsf.neuroimmunol.org
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unless otherwise stated.myocarditis [5,6], experimental systemic lupus erythe-
matosus [7] and experimental autoimmune encephalo-
myelitis (EAE) [2,8-10], the animal model for multiple
sclerosis (MS). Based on its potent effect in EAE
[11,12], oral statin treatment has been evaluated alone
or in combination with established drugs in clinical
MS trials [13-16]. In the first placebo-controlled trial
testing a statin as monotherapy in MS, atorvastatin
(AT) significantly reduced the risk of developing new
magnetic resonance imaging demyelinating lesions in
patients with clinical isolated syndromes, but did not
meet its primary endpoint that included reduction in
conversion to clinically definite MS [17,18].
Mechanistically, statins mediate pleiotropic effects on
various cells of the immune system [12]. In EAE, clinicalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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decreased expression of MHC class II molecules on
antigen-presenting cells and a reduced proliferation and
T-helper type (Th)-1 differentiation of myelin-reactive T
cells [2]. Statin-mediated immune modulation is not due
to cholesterol lowering and instead is attributed to the
inhibition of post-translational prenylation of small
GTP-binding proteins such as Ras, Rac and Rho [19].
Prenylation, a pathway branch for which HMG-CoA re-
ductase is also the rate-limiting enzyme, is required for
cell membrane anchoring and proper function of these
GTP-binding proteins involved in activation and dif-
ferentiation of immune cells. Downstream products of
these regulatory proteins form activator protein-1, which
coordinates with other transcription factors to induce
interferon gamma (IFNγ) transcription [20,21]. Statin-
mediated inhibition of protein prenylation therefore prob-
ably explains suppression of Th1-mediated autoimmunity
[19] as reported consistently from animal models. Statins
were furthermore shown to target multiple interleukin
(IL)-17 regulatory cytokines, leading also to an impaired
development of Th17 cells [22]. In many reports investi-
gating statins in various autoimmune settings, treatment
was also associated with the occurrence of Th2 cells,
whereas some studies reported clinical benefit without de-
velopment of an anti-inflammatory Th2 phenotype [3,23].
Whether statins solely inhibit encephalitogenic T-cell dif-
ferentiation or whether they may actively induce regula-
tory T-cell populations such as Th2 cells or Foxp3+ Tregs,
considered a desirable goal in treatment of MS, thus
remains to be investigated.
In this study we evaluated the kinetics of Th2 differen-
tiation following in vivo AT treatment. We also tested
the clinical relevance of AT-mediated Th2 differentiation
by AT treatment of signal transducer and activator of
transcription 6 (STAT6)-deficient mice, which cannot
generate IL-4-secreting Th2 cells [24]. AT treatment
ameliorated EAE in STAT6-deficient mice, indicating
that its clinical effects were not necessarily mediated
through induction of Th2 cells. Our further analysis
demonstrated that AT prevented expansion of encepha-
litogenic T cells in vivo, suggesting that the cytostatic ef-
fects of statins could contribute prominently to their




C57BL/6 female mice, 5 to 8 weeks of age, were pur-
chased from the Jackson Laboratory (Bar Harbor, MN,
USA). STAT6-deficient C57BL/6 mice [24] were ob-
tained from SJ Khoury (Harvard University, Cambridge,
MA, USA). B10.PL myelin basic protein Ac1-11-specific
T-cell receptor transgenic mice [25] were kindly providedby VK Kuchroo (Harvard University) and backcrossed to
B10.PL IL-4 green fluorescent protein-enhanced transcript
(4-GET) mice [26], which were obtained from R Locksley
(University of California, San Francisco, CA, USA). All
breeding and experiments were reviewed and approved by
the UCSF Institutional Animal Care and Use Committee
(Approval number AN077596) and followed the National
Institutes of Health guidelines for experimental research
on animals.
Peptides
Rat myelin basic protein peptide Ac1-11 (Ac-ASQKRPS
QRHG) was synthesized and purified (>99%) by Quality
Control Biochemicals, Inc. (Hopkinton, MA, USA). Mouse
myelin oligodendrocyte glycoprotein peptide 35 to 55
(MEVGWYRSPFSRVVHLYRNGK) was synthesized and
purified (>99%) by Auspep (Parkville, Australia).
Experimental autoimmune encephalomyelitis induction
Eight-week-old to 12-week-old female mice were used in
all EAE experiments. Mice on the B10.PL background
were injected subcutaneously with 100 μg myelin basic
protein Ac 1–11 in 0.1 ml phosphate-buffered saline
emulsified in an equal volume of complete Freund’s
adjuvant supplemented with 2 mg/ml Mycobacterium
tuberculosis H37RA on day 0 (DIFCO Laboratories,
Detroit, MI, USA). In C57BL/6 and C57BL/6 STAT6-
deficient mice, EAE was induced by immunization with
25 μg myelin oligodendrocyte glycoprotein peptide 35 to
55 in complete Freund’s adjuvant. After immunization
and 48 hours later, mice received an intravenous injec-
tion of 300 ng pertussis toxin in 0.2 ml phosphate-
buffered saline. Individual animals were evaluated daily,
and clinical scores were assessed in a blinded fashion as
follows: 0 = no clinical disease, 1 = loss of tail tone only,
2 =mild monoparesis or paraparesis, 3 = severe parapar-
esis, 4 = paraplegia and/or quadraparesis, and 5 =mori-
bund or death.
Atorvastatin treatment
AT (prescription formulation; Pfizer, Inc.) was brought
into suspension in phosphate-buffered saline as de-
scribed previously [2]. AT (1 mg/kg/day, 5 mg/kg/day or
10 mg/kg/day) was administered orally in 0.5 ml once
daily using a 20 mm feeding needle (Popper and Sons,
Inc., New York, USA) starting either 2 days prior to
immunization (prevention) or after mice developed a
clinical score ≥2 (reversal). Purified AT, used for in vitro
studies, was provided by Pfizer, Inc.
Assessment of proliferation
Ex vivo proliferative responses were measured using sple-
nocytes 12 days after immunization. Spleen cells (5 × 105)
were cultured in 0.2 ml RPMI medium supplemented
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100 μg/ml penicillin, and 100 μg/ml streptomycin. After
72 hours, cultures were pulsed with 1 μCi [3H]-thymi-
dine and harvested 16 hours later. Mean counts per mi-
nute of [3H] thymidine incorporation were calculated
for triplicate cultures. In vivo proliferation was evalu-
ated by injection of bromodeoxyuridine (BrdU). Then
200 μl of a 10 mg/ml BrdU solution were injected intra-
peritoneally 24 hours before evaluation of BrdU incorp-
oration by fluorescent-activated cell sorting (FACS)
using a BrdU Flow kit (Pharmingen, San Diego, CA,
USA).
Evaluation of T-cell differentiation
For in vitro evaluation of Th1 and Th2 differentiation,
naïve (Th0) cells were isolated from B10.PL 4GET T-cell
receptor mice by negative selection for CD3 using a
MACS separation system (Miltenyi Biotec Boston, MA,
USA). T cells were activated by plate-bound anti-CD3
(0.5 μM) and anti-CD28 (1 μM) in the presence of 50
U/ml IL-2 and various concentrations of AT. Addition
of 50 μg/ml anti-IFNγ (XMG 1.2) and 50 ng/ml mouse
IL-4 or of 20 μg/ml anti-IL-4 and 5 ng/ml IL-12 was
used as positive control or negative control for Th2
differentiation, respectively. IL-4-reporting GFP pro-
duction of T cells was evaluated by FACS. For ex vivo
analysis, splenocytes or lymph node cells were obtained
from B10.PL 4GET T-cell receptor mice 12 days after
immunization. Single cell preparations were evaluated for
IL-4-reporting GFP production of T cells by FACS stain-
ing for CD3. As a control, Th2 differentiation was deter-
mined in parallel by intracellular FACS staining for IL-4
(eBioscience, San Diego, CA, USA) after 5 hours of stimu-
lation with PMA phorbol 12-myristate 13-acetate and
ionomycin. Induction of CD4+CD25+FoxP3+ Tregs was
evaluated using a FACS staining kit by eBioscience.
Cytokine analysis
Culture supernatants were collected for cytokine analysis
at various time points: 48 hours (IL-12), 72 hours (tumor
necrosis factor, IFNγ, IL-17, transforming growth factor
beta), and 120 hours (IL-4 and IL-10). Enzyme-linked
immunosorbent assay (ELISA) was performed using
paired monoclonal antibodies specific for corresponding
cytokines following the manufacturer’s recommenda-
tions (Pharmingen). The results for ELISA assays are
expressed as an average of triplicate wells ± standard
error of the mean. The SOFTmax ELISA plate reader
and software were used for data analysis (Molecular De-
vices Corporation, Sunnyvale, CA, USA).
Histopathology
Brains and spinal cords were fixed in 10% formalin. Sec-
tions were stained with hematoxylin and eosin. Meningealand parenchymal inflammatory lesions were counted as
described previously [27].
Statistical analysis
Data are presented as the mean ± standard error of the
mean. For clinical scores, significance between groups
was examined using the Mann–Whitney U test; P < 0.05
was considered significant. All other statistical analysis
was performed using a one-way multiple-range analysis
of variance test for multiple comparisons; P < 0.01 was
considered significant.
Results
Atorvastatin treatment promotes development of Th2
cells in vitro, but not in vivo
To evaluate the kinetics of AT-mediated induction of
Th2 cells, we tested AT treatment in mice expressing
IL-4 linked via a viral IRES element with enhanced green
fluorescent protein (eGFP). These IL-4 4-GET reporter
mice were shown to faithfully report the evolution of
IL-4-expressing Th2 cells in vivo [26,28]. Using Th2-
polarizing cytokines, we first confirmed that naïve T cells
isolated from 4-GET mice differentiate into eGFP+ T cells
in vitro (Additional file 1: Figure S1). We then tested the
ability of AT to promote Th2 differentiation of naïve T
cells upon αCD3/αCD28 stimulation. As shown in Figure 1a,
4-hour preincubation with 5 μM AT facilitated the develop-
ment of IL4-producing Th2 cells when these cells were
subsequently stimulated in media not containing AT.
In contrast, continuous exposure to the same dose
during αCD3/αCD28 stimulation inhibited expansion
of naïve T cells, indicating that Th2 differentiation pri-
marily occurred upon recovery from statin exposure
(Figure 1b). As shown in Figure 1c, preincubation of
naïve T cells with 1 μM, 5 μM and 10 μM AT led to a
dose-dependent Th2 differentiation as evaluated 5 days
after stimulation. Upon continuous exposure to the
same doses (Figure 1d), 1 μM AT promoted a Th2 bias
whereas higher doses again impaired T-cell expansion.
To evaluate the effect of oral AT treatment in vivo,
4-GET mice were treated daily with 1 mg/kg/day, 5 mg/
kg/day or 10 mg/kg/day AT starting 2 days prior to
immunization. These doses have been previously shown
to prevent EAE [2]. As shown in Figure 2a (day 0), eGFP+
Th2 cells were not detectable in splenocytes isolated from
AT-treated 4-GET mice. It remained possible that a minor
population of IL-4-producing Th2 cells were generated in
response to in vivo AT treatment, but were not detected
by this method. We therefore also measured the intra-
cellular level of IL-4 by T cells by flow cytometry. AT
treatment at 10 mg/kg/day did not promote in vivo tran-
scription of IL-4 in T cells detectable by this method ei-
ther (Figure 2b). As a positive control, mice were treated
daily with glatiramer acetate (GA) at a dose of 150 μg,
Figure 1 T-helper type 2 cell differentiation upon in vitro atorvastatin treatment. Naïve T cells isolated from transgenic interleukin
(IL)-4-reporter (green fluorescent protein (GFP)-enhanced transcript) mice were incubated with 1, 5 or 10 μM atorvastatin (AT) either 4 hours prior
to stimulation (preincubation; (a), (c)) or continuously while stimulated ((b), (d)) with 0.5 μg/ml αCD3 and 1 μg/ml αCD28. Expression of
IL-4-reporting GFP was evaluated by fluorescence-activated cell sorting at the time-point indicated. (d) Expansion of T cells was visualized by
forward scatter (FSC)–side scatter (SSC). Shown is one representative out of three independent experiments.
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in vivo [29]. Similarly, IL-4 secretion was evident by
ELISA in freshly isolated T cells from GA-treated mice,
but not T cells from AT-treated mice (Figure 2c). As lym-
phocytes had been re-stimulated with antigen ex vivo in
previous studies that observed Th2 polarization with AT
treatment, we also examined T cells from AT-treated 4-
GET mice after various times of antigen re-stimulation
ex vivo in the absence of AT. To evaluate whether Th2 de-
viation of T cells may occur as a secondary effect following
in vivo AT treatment, splenocytes obtained from in vivo
AT-treated mice were taken into culture. As shown in
Figure 2a, without in vitro stimulation, T cells isolated
from AT-treated mice but not from control-treated mice
developed into eGFP+, IL-4-producing Th2 cells starting
on day 4. The extent of this in vitro Th2 deviation corre-
lated with the dose of AT used for in vivo treatment and
occurred with a maximum after 6 days of in vitro culture.
These results were confirmed when IL-4 secretion by
in vitro cultured T cells isolated from AT-treated and GA-
treated mice was compared by ELISA (Figure 2c).
Atorvastatin treatment prevents and reverses EAE in
STAT6-deficient mice
Because we did not observe Th2 polarization during
in vivo AT treatment, we evaluated whether STAT6-dependent development of Th2 cells was required for the
clinical benefit mediated by AT treatment of EAE. Here,
we investigated whether AT treatment was effective in
STAT6-deficient mice, which are incapable of generating
IL4-producing Th2 cells [24]. Although STAT6-deficient
mice developed slightly more severe EAE than control-
treated wild-type mice [24] (Figure 3a), in vivo AT treat-
ment both prevented EAE and reversed paralysis in
STAT6-deficient mice, comparable with its effect in wild-
type mice (Figure 3a). Similar results were obtained in
wild-type or STAT6-deficient mice treated with oral AT at
a dose of 1 mg/kg/day, the equivalent of the highest US
Food and Drug Administration-approved dose of 80 mg/
day in humans (Figure 3a). As shown in Figure 3b, oral
AT (1 mg/kg/day) reduced the number of CNS inflamma-
tory lesions in a similar manner in of STAT6-deficient
mice and wild-type mice. Reduction in CNS inflammation
occurred when treatment started prior to immunization
(left panel) or after disease was established (right panel).
AT treatment of wild-type mice has been associated
with inhibition of T-cell proliferation and reduction in
proinflammatory cytokine production [2,8]. As shown in
Figure 4a, AT treatment of STAT6-deficient mice was
also associated with reduction of both T-cell prolifera-
tion and secretion of tumor necrosis factor, IFNγ and
























Figure 2 T-helper type 2 cell differentiation occurs in vitro following in vivo atorvastatin treatment. (a) Interleukin (IL)-4-reporter (green
fluorescent protein (GFP)-enhanced transcript) mice were fed daily with 1, 5 or 10 mg/kg/day atorvastatin (AT) for 12 days starting 2 days prior to
immunization with myelin basic protein Ac1-11. Splenic T cells were washed, taken into culture and evaluated daily for production of
IL-4-reporting GFP. Ex vivo IL-4 production by T cells was also evaluated by (b) intracellular cytokine staining (day 0, gated on CD4+ T cells) and
(c) enzyme-linked immunosorbent assay (supernatants taken at the time points indicated); mice injected subcutaneously daily with 150 μg glatiramer
acetate (GA) in phosphate-buffered saline (PBS) served as positive control. Five mice/group were used. Shown is one representative finding out of
three independent experiments performed. FITC, fluorescein isothiocyanate.
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does not require STAT6 signaling. Interestingly, AT
treatment was associated with increased IL-10 secretion.
However, it was not associated with an increase in
CD4+CD25+FoxP3+ Tregs in either STAT6-deficient
or wild-type mice. As a positive control, and consist-
ent with previous observations [29-32], GA-treatment
promoted Treg expansion in mice (Figure 4b).
Atorvastatin treatment inhibits T-cell proliferation in vivo
We observed that in vivo AT treatment during EAE
inhibited proliferation of myelin-specific T cells upon re-
stimulation ex vivo [2,8] (Figure 4a), suggesting that
these myelin-reactive cells expanded less in AT-treated
mice post vaccination. A reduction in expansion of
myelin-reactive T cells would also explain the loweredproinflammatory cytokine production observed by these
cells. Thus, we further explored the anti-proliferative ef-
fects of AT in vitro and in vivo. In vitro, AT inhibited
the proliferation of both differentiated Th1 and Th2 cells
(Figure 5a); and following in vivo AT treatment, T cells
exhibited a reduced ability to proliferate after ex vivo
stimulation with anti-CD3 and anti-CD28 (Figure 5b).
To evaluate whether oral AT treatment inhibited T-cell
proliferation in vivo in these disease settings, we ad-
ministered mice with BrdU, a pyrimidine nucleotide
analogue that is incorporated during DNA synthesis and
reflects cell division. As shown in Figure 5c, CD3+ T
cells from AT-treated mice showed almost no BrdU in-
corporation at 12 days post vaccination, thus confirming
that AT treatment had a potent anti-proliferative effect



























































































Figure 3 STAT6-deficient C57Bl/6 mice are fully protected by atorvastatin treatment. Signal transducer and activator of transcription 6
(STAT6)-deficient and wild-type (WT) C57Bl/6 mice were fed daily with atorvastatin (AT; 1 mg/kg/day or 10 mg/kg/day) or vehicle (phosphate-buffered
saline (PBS)) starting either 2 days prior to immunization (prevention, left panels) or after experimental autoimmune encephalomyelitis (EAE)
was fully established (reversal, right panels). (a) Mice were evaluated daily for clinical EAE symptoms. (b) At study termination, mice were sacrificed and
evaluated for histologic signs of EAE. Shown is the number of inflammatory lesions per three representative (cervical, thoracal, lumbal) hematoxylin
and eosin-stained spinal cord sections. Twelve mice/group were used; two independent studies were performed for each setting.
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AT and other cholesterol-lowering statins have been
shown to be clinically beneficial in various models of T-
cell-mediated autoimmune disease. These studies have
consistently reported that statin treatment inhibits pro-
inflammatory Th1 cytokine production. Despite the use
of various statins and differences in dose or route of ad-
ministration, many – but not all [3,6,23] – of these studies
attributed the benefit of statin treatment in autoimmune
models to development of Th2 cells [2,5,33,34]. Here we
used IL4-reporter mice and STAT6-deficient mice as tools
to further explore the involvement anti-inflammatory Th2
cells in the anti-inflammatory effects of AT. We found
that dosing of AT in vivo failed to promote detectable fre-
quencies of Th2 cells, but T cells isolated from AT-treated
mice did produce IL-4 in increased amounts after re-
stimulation in culture in the absence of AT. Similar results
were obtained when myelin-specific T cells were treatedwith AT in vitro; pre-incubation of naïve T cells prior to
activation led to a dose-dependent development of Th2
cells, whereas continuous exposure at higher doses in-
hibited T-cell activation and differentiation. The anti-
proliferative effect may thus be a dominant effect of AT.
Furthermore, we found that despite their inability to gen-
erate IL-4 producing T cells, STAT6-deficient mice were
fully protected from development of proinflammatory
Th1 and Th17 cells and clinical EAE by AT treatment.
Our results clearly demonstrate that Th2 polarization is
not required for the in vivo benefit of statin treatment in
CNS autoimmune disease. Finally, we provide strong evi-
dence that the anti-proliferative effect of AT probably ac-
counts for a good proportion of its effects in dampening
CNS autoimmunity.
By inhibiting HMG-CoA reductase, statins interfere
with the rate-limiting step in the mevalonate pathway that
generates cholesterol and isoprenoid derivatives, including
Figure 4 Atorvastatin treatment inhibits proliferation, Th1 and Th17 differentiation of myelin-reactive T cells but does not expand
CD4+CD25+FoxP3+ regulatory T cells. Splenocytes were isolated from signal transducer and activator of transcription 6 (STAT6)-deficient or
wild-type (WT) C57BL/6 mice dosed daily with atorvastatin (AT; 10 mg/kg/day) or vehicle (phosphate-buffered saline (PBS)) for 12 days starting
2 days prior to immunization with myelin oligodendrocyte glycoprotein peptide 35 to 55 (MOG 35–55). (a) Cytokine secretion in response to
MOG 35–55 was evaluated by enzyme-linked immunosorbent assay. (b) The frequency of CD4+CD25+FoxP3+ regulatory T cells (Tregs) was evaluated
by fluorescence-activated cell sorting. As positive control, mice were injected subcutaneously with 150 μg glatiramer acetate (GA) in PBS per day.
Shown is the percentage of CD4+CD25+ Tregs within all CD4+ T cells. Five mice/group were used. Shown is one representative finding out of two
independent experiments performed. cpm, counts per minute; FITC, fluorescein isothiocyanate; IFN, interferon; IL, interleukin; PE, phycoerythrin; TNF,
tumor necrosis factor.
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pyrophosphate. When studying T-cell differentiation
in vitro using farnesyl-pyrophosphate and all-trans
geranylgeranyl-pyrophosphate, as well as selective an-
tagonists, we previously demonstrated that farnesyla-
tion of the small GTP binding protein, Ras, is required
for Th1 differentiation and that geranylgeranylation of
RhoA is necessary for T-cell proliferation [19]. As statins
prevent production of both farnesyl-pyrophosphate and
all-trans geranylgeranyl-pyrophosphate, they can inhibit
both T-cell differentiation and proliferation, respectively.
As we did not observe Th1, Th2 or Th17 differentiation
in vivo during AT treatment, we questioned whether ATalso exerted a potent anti-proliferative effect in vivo. Here,
we observed that 1 mg/kg oral AT treatment, a dose ap-
proximately equivalent (weight/weight) to the 80 mg dose
administered in recent clinical MS trials, nearly shut down
T-cell proliferation in vivo in mice. These results, along
with the therapeutic effect in STAT6-deficient mice and
our inability to demonstrate Th2 polarization at the time
of AT treatment, suggest that the cytostatic effect of statin
treatment may provide the predominant mechanism re-
sponsible for observed benefits in MS clinical trials.
In our investigation, we observed that AT treatment
inhibited T-cell proliferation upon re-stimulation in vitro,
and did so in an antigen nonselective manner. Our data
Figure 5 Atorvastatin treatment inhibits proliferation of T cells in vivo. (a) Atorvastatin (AT) dose-dependently inhibits proliferation of both
differentiated T-helper type (Th)-1 and Th2 cells. Naïve T cells from interleukin (IL)-4-reporter (IL-4 green fluorescent protein-enhanced transcript
(4GET)) mice were stimulated with 0.5 μg/ml αCD3 in the presence of 20 μg/ml αIL-4 and 5 ng/ml IL-12 (Th1 condition, left panel) or 50 μg/ml
α-interferon (IFN)-γ and 50 ng/ml IL-4 (Th2 condition, right panel). Respective polarization of T cells was confirmed at day 5. Differentiated T cells
were then washed and re-stimulated with the indicated concentrations of αCD3 in the presence of 0, 1 or 10 μM AT. T-cell proliferation was
assessed by H3 incorporation. Shown is one representative out of three independent experiments. (b) T cells isolated from IL-4-reporter (4GET)
mice treated with 10 mg/kg/day AT for 12 days starting 2 days prior to immunization were evaluated for proliferation following activation with
the indicated dose of αCD3. (c) IL4-reporter (4GET) mice were immunized with myelin basic protein Ac 1–11. Starting 2 days prior to
immunization, mice were fed daily with 10 mg/kg/day AT for 12 days. Twenty-four hours before T-cell isolation, mice were injected intraperitoneally
with 200 μl of a 10 mg/ml bromodeoxyuridine (BrdU) solution. BrdU incorporation of freshly isolated, splenic T cells was evaluated by
fluorescence-activated cell sorting staining for CD3 and BrdU. Five mice/group were used. Shown is one representative finding out of three
independent experiments performed. cpm, counts per minute.
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who demonstrated that AT mediated inhibition of T-cell
proliferation in vitro, which was linked to downregulation
of cyclin-dependent kinase 4. Interestingly, a predominant
anti-proliferative effect rather than induction of Th2 cells
could also explain the benefit of statin treatment in Th2-
mediated and B-cell-mediated models of allergic asthma
[35] and systemic lupus erythematosus [7], respectively.While our data demonstrate that Th2 polarization is
not required for the beneficial immunomodulatory effect
of statin treatment, they do not exclude the contribution
of statin-induced anti-inflammatory cytokines. In this re-
gard, the clinical benefit mediated by AT treatment was
associated with an increased secretion of IL-10. There
are a number of immune cell populations that express
IL-10, including B regulatory cells and anti-inflammatory
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cell(s) other than T cells may also be producers of IL-10 in
AT-treated mice. Interestingly, our results are reminiscent
of findings from one of the first monotherapy MS trials. In
that MS trial, high-dose AT treatment led to a reduction
in the number and volume of newly emerging CNS le-
sions, and was associated with an enhanced secretion of
IL-10, but not IL-4 [36].
Data indicate that there is a reduction in Treg number
and function in MS. Restoration of the Treg balance ap-
pears to be an important mechanism of action of GA in
MS [29,30,37,38]. Interestingly, there are only limited data
suggesting that statins may promote expansion of Tregs
[39-41]. We found that neither treatment initiated prior to
disease induction nor following EAE onset altered the fre-
quency of CD4+CD25+Foxp3+ Tregs in diseased mice. A
potential increase in Tregs is therefore unlikely to signifi-
cantly contribute to the anti-inflammatory effect of statins
in CNS autoimmune disease.
How does this new information impact the potential
use of statins in MS [42]? At first glance, nonspecific in-
hibition of proinflammatory T-cell differentiation in MS
may be viewed less advantageously than the active induc-
tion of an anti-inflammatory T-cell phenotype [17,18,43].
Interestingly, a recent clinical trial in secondary pro-
gressive MS further suggests that simvastatin may slow
progression and that this effect also occurs largely inde-
pendent of peripheral immune modulation [44]. Taken
together, these trials demonstrate that statin treatment
is beneficial at various stages in the disease. One strat-
egy may be to use statins in combination with approved
MS drugs. Several recent trials have investigated the
combination of statins with IFNβ [13-16]. While results
are not unequivocal [45], two of these studies suggested
that addition of oral statin to IFNβ therapy may result
in a paradoxical increase of MS activity [13-16]. In gen-
eral, for two agents to exert synergistic benefit, distinct
mechanisms of action are desirable, while employing
the same mechanism may increase the risk of antagon-
ism [46]. Statins and GA have complementary mecha-
nisms of action [47]. Whereas GA promotes induction
of both Th2 cells and Tregs [29,30,37], statins have been
associated with a Th2 bias in treatment of CNS auto-
immunity and, as we have shown in this study, a prom-
inent anti-proliferative effect. In EAE, this combination
had a synergistic beneficial effect [47]. However, clinical
trials will be necessary to determine whether such a
combination will elicit a clinical beneficial effect in MS.
One may exercise caution when testing statins in com-
bination with more recently approved MS therapeutic
agents. In this regard, it is important to recognize that
by inhibiting de novo pyrmidine synthesis, teriflunomide
has a primary cytostatic effect on proliferating lympho-
cytes [48,49]. While the clinical benefit of dimethylfumarate has been attributed to its activation of the anti-
oxidant transcription factor (erythroid-derived 2)-related
factor (Nrf2) pathway [49,50], it also exerts anti-
proliferative activity [51]. Given the strong in vivo anti-
proliferative effects of AT, one might envisage testing a
short course of high-dose oral statin as an adjunct to, or
in lieu of, high-dose intravenous or oral steroids for MS
exacerbations.Additional file
Additional file 1: Figure S1. Showing naïve T cells isolated from
transgenic IL-4-reporter (4-GET) mice stimulated with 0.5 μg/ml αCD3
and 1 μg/ml αCD28 in the presence of 50 μg/ml anti-IFNγ and 50 ng/ml
mouse IL-4 (Th2 condition), 20 μg/ml anti-IL-4 and 5 ng/ml IL-12 (Th1
condition) or without any supplementation (neutral). Expression of IL-4-
reporting green fluorescent protein (GFP) was evaluated by FACS 5 days
after stimulation. Shown is one representative out of five independent
experiments.
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